Leash Bio Announces Multi-Target Agreement with Monte Rosa Therapeutics

October 16, 2025

“We’re thrilled to announce that Leash Biosciences has signed a multi-target agreement with Monte Rosa Therapeutics! Under the terms of the agreement, Leash will provide novel chemistries in exchange for certain economics from Monte Rosa. The companies are confident that this first partnership has the potential to accelerate the discovery of novel degraders for difficult-to-drug therapeutic targets.

We believe a partnership with the thoughtful folks at Monte Rosa will yield fantastic results for patients in need. Our proprietary platform allows us to identify novel binders against difficult therapeutic targets with incredible speed. Because we screen as much as we do, we had identified tractable material for over 500 targets before conversations with Monte Rosa even started. This has massively accelerated the whole endeavor such that the first tranche of compounds has already been received for deeper evaluation by the Monte Rosa team.

We’re particularly excited about how aligned our teams are in thinking about the problem of identifying good stuff for novel targets at scale. At Leash, we identify targets, identify likely binding surfaces on those targets, produce large numbers of mutants of those surfaces, and then screen that whole collection of proteins against many millions of proprietary molecules each. This way, we get SAR of chemical series and structural information about the binding mode all at once. Combining our approach with Monte Rosa’s drug discovery engine is the stuff that dreams are made of – let’s get to work!”

-Ian Quigley, Founder, Leash Bio